Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$105,000.00

Characterizing biomarkers capable of predicting treatment response to an anti-inflammatory agent in adults with bipolar depression: results from a double-blinded, placebo-controlled clinical trial of infliximab using machine learning approaches

EF 2018-19

Résumé
Depression is a common, pervasive, and highly disabling brain-based illness and affects approximately 1 in 8 Canadians in their lifetime. Despite the availability of interventions with demonstrated efficacy in clinical trials, approximately one-third of depressed patients have tried multiple interventions without experiencing improvements in their symptoms or ability to function at home, work, or school. Novel interventions for depression are needed to improve clinical outcomes in this vulnerable subpopulation. Moreover, novel approaches to personalize treatment recommendations are needed to improve clinical outcomes, as patients are currently recommended treatments based on evidence of efficacy aggregated from many different patients with depression, rather than their own medical history, biological characteristics, or needs. Preliminary studies of treatments targeting molecular imbalances and alterations in the immune-inflammatory system have successfully treated depressed adults. We recently conducted a clinical trial investigating the efficacy of an anti-inflammatory treatment for depression. In our sample of 60 adults with depression, treatment outcomes varied significantly among subjects: using machine learning approaches, I will characterize blood biomarkers and clinical features capable of identifying patients who are likely, or unlikely, to respond to treatment. I hypothesize that pre-treatment blood levels of inflammatory and metabolic substrates relevant to the neurobiology and treatment of depression will predict treatment outcomes in adults with depression. Our findings will inform clinicians on personalized treatment decisions and reduce the morbidity associated with depression.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
408168
Name
Lee Yena
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing biomarkers capable of predicting treatment response to an anti-inflammatory agent in adults with bipolar depression: results from a double-blinded, placebo-controlled clinical trial of infliximab using machine learning approaches
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Anti-Inflammatory; Bipolar; Classification And Regression Trees; Clinical Trial; Depression; Inflammation; Machine Learning; Metabolic; Mood Disorders; Treatment
Abstract
Depression is a common, pervasive, and highly disabling brain-based illness and affects approximately 1 in 8 Canadians in their lifetime. Despite the availability of interventions with demonstrated efficacy in clinical trials, approximately one-third of depressed patients have tried multiple interventions without experiencing improvements in their symptoms or ability to function at home, work, or school. Novel interventions for depression are needed to improve clinical outcomes in this vulnerable subpopulation. Moreover, novel approaches to personalize treatment recommendations are needed to improve clinical outcomes, as patients are currently recommended treatments based on evidence of efficacy aggregated from many different patients with depression, rather than their own medical history, biological characteristics, or needs. Preliminary studies of treatments targeting molecular imbalances and alterations in the immune-inflammatory system have successfully treated depressed adults. We recently conducted a clinical trial investigating the efficacy of an anti-inflammatory treatment for depression. In our sample of 60 adults with depression, treatment outcomes varied significantly among subjects: using machine learning approaches, I will characterize blood biomarkers and clinical features capable of identifying patients who are likely, or unlikely, to respond to treatment. I hypothesize that pre-treatment blood levels of inflammatory and metabolic substrates relevant to the neurobiology and treatment of depression will predict treatment outcomes in adults with depression. Our findings will inform clinicians on personalized treatment decisions and reduce the morbidity associated with depression.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lee, Yena
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~